Gifting allows recipients to access the article for free. Charles River Laboratories, a Wilmington, Mass., pharma services ...

Charles River has been riding rough waters in 2024, and as the CRO’s CEO predicted, the third quarter proved no exception. | ...

A group of over 80 Canadian academics is urging the federal government to halt the importation of endangered macaque monkeys ...

Charles River Laboratories International Inc (NYSE:CRL) reported third-quarter 2024 revenue of $1.01 billion on Wednesday, a ...

Have you evaluated the performance of Charles River Laboratories' (CRL) international operations for the quarter ending September 2024? Given the extensive global presence of this medical research ...

Charles River Laboratories raised its full-year profit forecast after beating analysts' estimates for quarterly results as the contract research firm expects demand to stabilize from biotech clients ...

In another sign that biopharma companies are slowing their early R&D efforts, Charles River Laboratories is shuttering more than a dozen sites. The service provider is working on “consolidating ...

UBS raised the firm’s price target on Charles River (CRL) to $250 from $240 and keeps a Buy rating on the shares post the earnings ...

WILMINGTON, Mass. — WILMINGTON, Mass. — Charles River Laboratories International Inc. (CRL) on Wednesday reported third-quarter earnings of $69.7 million. On a per-share basis, the Wilmington, ...

Charles River Labs (CRL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tejas Savant from Morgan Stanley maintained a Hold rating on the ...

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2024. For the quarter, revenue was $1.01 billion, a ...